Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

367
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
367
Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

2.7K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
2.7K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

479
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
479
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

379
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
379
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

324
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
324
Hypersensitivities01:30

Hypersensitivities

843
Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
843

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effectiveness and probability of full disease control with canakinumab in familial Mediterranean fever: real-world data from the AIDA Network.

Rheumatology (Oxford, England)·2026
Same author

Real-Life Effectiveness and Safety of Lebrikizumab in Elderly Patients with Atopic Dermatitis: A Multicenter Study.

Clinical and experimental dermatology·2026
Same author

Distinctive Reactivity to the C-terminal Epitope of BP180 Characterizes Immune Checkpoint Inhibitor-associated Bullous Pemphigoid, and an ELISA Based on the BP180 Ectodomain Enables Prompt Diagnosis in a Subset of Patients.

Acta dermato-venereologica·2026
Same author

The Evolving Landscape of Contact Dermatitis Diagnosis: A Critical Appraisal of Recent Regulatory Constraints.

La Medicina del lavoro·2026
Same author

<i>Letter:</i> Real-Life Improvement in Quality of Life With Delgocitinib in Chronic Hand Eczema.

Dermatitis : contact, atopic, occupational, drug·2026
Same author

Meta-inflammation in Hidradenitis suppurativa: from pathogenic evidence to therapeutic approaches.

Frontiers in immunology·2026

Related Experiment Video

Updated: Aug 2, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.0K

Emerging Systemic Treatments for Atopic Dermatitis.

Silvia Mariel Ferrucci1, Simona Tavecchio2, Angelo Valerio Marzano3,2

  • 1Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, via Pace 9, 20122, Milan, Italy. silviaferrucci@hotmail.com.

Dermatology and Therapy
|April 18, 2023
PubMed
Summary

New systemic therapies for atopic dermatitis (AD) are emerging, targeting key inflammatory pathways like interleukin-4 and interleukin-13. This review highlights promising agents for AD treatment, focusing on their efficacy and safety.

Keywords:
Atopic dermatitisDupilumabMonoclonal antibodiesSmall molecules

More Related Videos

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
06:47

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment

Published on: September 27, 2017

9.7K
Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.2K

Related Experiment Videos

Last Updated: Aug 2, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.0K
Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
06:47

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment

Published on: September 27, 2017

9.7K
Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.2K

Area of Science:

  • Dermatology
  • Immunology
  • Pharmacology

Background:

  • Atopic dermatitis (AD) is a chronic inflammatory skin disease influenced by genetics and environment.
  • AD impairs skin barrier function, alters skin microbiota, and involves immune dysregulation, significantly impacting quality of life.
  • Current treatments include topical agents, phototherapy, and systemic immunosuppressants, with dupilumab offering a significant advancement.

Purpose of the Study:

  • To review promising systemic agents currently under investigation for atopic dermatitis.
  • To illustrate the efficacy, safety, and tolerability of novel therapeutic options for AD.
  • To explore emerging targets beyond the type 2 inflammatory cascade.

Main Methods:

  • Literature review of systemic agents for atopic dermatitis.
  • Analysis of novel therapies targeting inflammatory cascades and signaling pathways.
  • Evaluation of efficacy, safety, and tolerability data for investigational drugs.

Main Results:

  • Dupilumab, a monoclonal antibody targeting IL-4 receptor α, has shown efficacy in moderate-to-severe AD.
  • New systemic therapies, primarily monoclonal antibodies, target type 2 inflammation (IL-4, IL-13) and JAK signaling.
  • Emerging research considers other T-helper cell subtypes (Th1, Th22) and cytokines like IL-31 for pruritus management.

Conclusions:

  • The therapeutic landscape for atopic dermatitis is expanding with novel systemic agents.
  • Targeting specific cytokines and signaling pathways offers new hope for effective AD management.
  • Further research is crucial to understand the full potential and safety of these emerging treatments.